Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone805-447-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$23.75 billion
Profitability
Miscellaneous
Employees21,500
Next Earnings Date1/30/2020 (Confirmed)
OptionableOptionable
Amgen (NASDAQ:AMGN) Frequently Asked Questions
What is Amgen's stock symbol?
Amgen trades on the NASDAQ under the ticker symbol "AMGN."
How often does Amgen pay dividends? What is the dividend yield for Amgen?
Amgen announced a quarterly dividend on Wednesday, December 11th. Investors of record on Friday, February 14th will be paid a dividend of $1.60 per share on Friday, March 6th. This represents a $6.40 dividend on an annualized basis and a dividend yield of 2.70%. The ex-dividend date is Thursday, February 13th. This is a positive change from Amgen's previous quarterly dividend of $1.45. View Amgen's Dividend History.
How will Amgen's stock buyback program work?
Amgen declared that its Board of Directors has approved a stock repurchase program on Friday, February 2nd 2018, which authorizes the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to buy shares of its stock through open market purchases. Shares buyback programs are often a sign that the company's management believes its shares are undervalued.
How were Amgen's earnings last quarter?
Amgen, Inc. (NASDAQ:AMGN) released its quarterly earnings data on Tuesday, October, 29th. The medical research company reported $3.66 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $3.53 by $0.13. The medical research company earned $5.74 billion during the quarter, compared to analysts' expectations of $5.63 billion. Amgen had a net margin of 34.48% and a return on equity of 80.26%. The business's revenue was down 2.8% compared to the same quarter last year. During the same quarter last year, the company earned $3.69 EPS. View Amgen's Earnings History.
When is Amgen's next earnings date?
How can I listen to Amgen's earnings call?
Amgen will be holding an earnings conference call on Thursday, January 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Amgen issued on next quarter's earnings?
Amgen updated its FY 2019
Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of $$14.50-14.70 for the period, compared to the Thomson Reuters consensus estimate of $$14.44. The company issued revenue guidance of $$23.1-23.3 billion, compared to the consensus revenue estimate of $$23.01 billion.
What price target have analysts set for AMGN?
22 brokers have issued 12-month price objectives for Amgen's stock. Their forecasts range from $198.00 to $277.00. On average, they anticipate Amgen's share price to reach $237.50 in the next twelve months. This suggests a possible upside of 0.3% from the stock's current price. View Analyst Price Targets for Amgen.
What is the consensus analysts' recommendation for Amgen?
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 9 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amgen.
What are Wall Street analysts saying about Amgen stock?
Here are some recent quotes from research analysts about Amgen stock:
- 1. William Blair analysts commented, "We ultimately view the deal as positive for Amgen and a good fit for management’s strategy given the low-risk nature of the deal and immediate accretion." (8/30/2019)
- 2. Evercore ISI analysts commented, "We used a discount rate which is a function of cost of equity and cost of debt. Terminal growth rate estimates were used to derive future cash flows." (8/11/2019)
- 3. According to Zacks Investment Research, "While Amgen’s newer drugs — Prolia, Xgeva, Blincyto, Kyprolis — will drive sales, biosimilar and brand competition faced by its legacy drugs will create pressure on the top line in 2019. Meanwhile, uptake of key drug, Repatha has been slow due to payer restrictions. However, Amgen is progressing well with its pipeline and approval of Aimovig was a huge boost. In the past five years, Amgen has launched nine products, including two in new therapeutic areas. Amgen boasts a strong biosimilars pipeline, which could be an important long-term growth driver for the company. Amgen’s restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some support to the bottom line. Amgen’s shares have underperformed the industry this year so far. Estimates have declined lightly ahead of the Q1 earnings release. Amgen has a positive record of earnings surprises in recent quarters." (4/15/2019)
- 4. Mizuho analysts commented, "We think the peak sales potential of Vascepa is underappreciated. Therefore, upward earnings revisions to levels not reflected in FactSet consensus expectations should drive AMRN shares higher. Valuation Summary We continue to use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $35." (4/12/2019)
- 5. Cantor Fitzgerald analysts commented, ". We Reiterate our Neutral rating and $221 Price Target. We are attending the AACR (cancer research meeting) in Atlanta. Amgen presented its preclinical data for 24-minute session. The company’s molecule is targeting the KRAS p.G12C mutation and is a covalent inhibitor. The presentation explained how it identified a unique groove formed by rotation of an adjacent histidine residue (H95). An inactive form of KRAS reveals a small pocket P2 in GDP-KRAS, which is adjacent to cys12. The molecule binds to P2 and H95 and is expected to be dosed orally once daily. 510 has single-digit nanomolar potency and is 1,000x more selective to other KRAS mutants." (4/1/2019)
Has Amgen been receiving favorable news coverage?
News coverage about AMGN stock has trended negative on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amgen earned a daily sentiment score of -2.3 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Amgen.
Are investors shorting Amgen?
Amgen saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 9,910,000 shares, an increase of 8.2% from the December 15th total of 9,160,000 shares. Based on an average daily trading volume, of 2,130,000 shares, the days-to-cover ratio is currently 4.7 days. Currently, 1.7% of the shares of the company are sold short. View Amgen's Current Options Chain.
Who are some of Amgen's key competitors?
Some companies that are related to Amgen include Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).
What other stocks do shareholders of Amgen own?
Who are Amgen's key executives?
Amgen's management team includes the folowing people:
- Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 56)
- Mr. David W. Meline, Exec. VP & CFO (Age 62)
- Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 58)
- Dr. David M. Reese M.D., Exec. VP of R&D (Age 56)
- Mr. Murdo Gordon, Exec. VP of Global Commercial Operations (Age 52)
Who are Amgen's major shareholders?
Amgen's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Johanson Financial Advisors Inc. (0.20%), Candriam Luxembourg S.C.A. (0.15%), PGGM Investments (0.09%), Douglass Winthrop Advisors LLC (0.05%), Nisa Investment Advisors LLC (0.05%) and Gateway Investment Advisers LLC (0.05%). Company insiders that own Amgen stock include Cynthia M Patton, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar, Sean E Harper and Tyler Jacks. View Institutional Ownership Trends for Amgen.
Which institutional investors are selling Amgen stock?
AMGN stock was sold by a variety of institutional investors in the last quarter, including PGGM Investments, Commerzbank Aktiengesellschaft FI, Gateway Investment Advisers LLC, Tocqueville Asset Management L.P., Meag Munich Ergo Kapitalanlagegesellschaft MBH, Creative Financial Designs Inc. ADV, State of Alaska Department of Revenue and Nisa Investment Advisors LLC. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, David W Meline, Jonathan P Graham, R Sanders Williams and Ronald D Sugar. View Insider Buying and Selling for Amgen.
Which institutional investors are buying Amgen stock?
AMGN stock was acquired by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., DNB Asset Management AS, Manning & Napier Group LLC, Fluent Financial LLC, Zurcher Kantonalbank Zurich Cantonalbank, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Exchange Traded Concepts LLC and Janney Montgomery Scott LLC. View Insider Buying and Selling for Amgen.
How do I buy shares of Amgen?
Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Amgen's stock price today?
One share of AMGN stock can currently be purchased for approximately $236.72.
How big of a company is Amgen?
Amgen has a market capitalization of $140.65 billion and generates $23.75 billion in revenue each year. The medical research company earns $8.39 billion in net income (profit) each year or $14.40 on an earnings per share basis. Amgen employs 21,500 workers across the globe.View Additional Information About Amgen.
What is Amgen's official website?
How can I contact Amgen?
Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]
MarketBeat Community Rating for Amgen (NASDAQ AMGN)
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe AMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
